Talpaz M - Search Results

1

Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis.

Pardanani A, Gotlib JR, Jamieson C, Cortes JE, Talpaz M, Stone RM, Silverman MH, Gilliland DG, Shorr J, Tefferi A. Pardanani A, et al. Among authors: talpaz m. J Clin Oncol. 2011 Mar 1;29(7):789-96. doi: 10.1200/JCO.2010.32.8021. Epub 2011 Jan 10. J Clin Oncol. 2011. PMID: 21220608 Free PMC article. Clinical Trial.

2

Serum levels of interleukin-10 in patients with diffuse large cell lymphoma: lack of correlation with prognosis.

Cortes JE, Talpaz M, Cabanillas F, Seymour JF, Kurzrock R. Cortes JE, et al. Among authors: talpaz m. Blood. 1995 May 1;85(9):2516-20. Blood. 1995. PMID: 7537119 Free article.

3

Philadelphia chromosome-negative chronic myelogenous leukemia with rearrangement of the breakpoint cluster region. Long-term follow-up results.

Cortes JE, Talpaz M, Beran M, O'Brien SM, Rios MB, Stass S, Kantarjian HM. Cortes JE, et al. Among authors: talpaz m. Cancer. 1995 Jan 15;75(2):464-70. doi: 10.1002/1097-0142(19950115)75:2<464::aid-cncr2820750209>3.0.co;2-e. Cancer. 1995. PMID: 7812917

4

Result of interferon-alpha therapy in patients with chronic myelogenous leukemia 60 years of age and older.

Cortes J, Kantarjian H, O'Brien S, Robertson LE, Pierce S, Talpaz M. Cortes J, et al. Among authors: talpaz m. Am J Med. 1996 Apr;100(4):452-5. doi: 10.1016/s0002-9343(97)89522-8. Am J Med. 1996. PMID: 8610733 Clinical Trial.

5

Chronic myelogenous leukemia: a review.

Cortes JE, Talpaz M, Kantarjian H. Cortes JE, et al. Among authors: talpaz m. Am J Med. 1996 May;100(5):555-70. doi: 10.1016/s0002-9343(96)00061-7. Am J Med. 1996. PMID: 8644769 Review.

6

Treatment of chronic myelogenous leukemia with nucleoside analogs deoxycoformycin and fludarabine.

Cortes J, Kantarjian H, Talpaz M, O'Brien S, Beran M, Koller C, Keating M. Cortes J, et al. Among authors: talpaz m. Leukemia. 1997 Jun;11(6):788-91. doi: 10.1038/sj.leu.2400677. Leukemia. 1997. PMID: 9177428 Clinical Trial.

7

A pilot study of all-trans retinoic acid in patients with Philadelphia chromosome-positive chronic myelogenous leukemia.

Cortes J, Kantarjian H, O'Brien S, Beran M, Estey E, Keating M, Talpaz M. Cortes J, et al. Among authors: talpaz m. Leukemia. 1997 Jul;11(7):929-32. doi: 10.1038/sj.leu.2400682. Leukemia. 1997. PMID: 9204970

8

Thiotepa for the treatment of thrombocythemia in patients with Philadelphia chromosome positive chronic myelogenous leukemia.

Rodriguez-Monge EJ, Cortes JE, O'Brien S, Talpaz M, Kantarjian HM. Rodriguez-Monge EJ, et al. Among authors: talpaz m. Cancer. 1997 Aug 1;80(3):396-400. doi: 10.1002/(sici)1097-0142(19970801)80:3<396::aid-cncr7>3.0.co;2-q. Cancer. 1997. PMID: 9241073

9

Effects of interferon-alpha therapy on lymphocyte subpopulations in patients with chronic myeloid leukemia.

Sacchi S, Cortes J, Kantarjian H, Talpaz M. Sacchi S, et al. Among authors: talpaz m. Hematopathol Mol Hematol. 1997-1998;11(1):41-7. Hematopathol Mol Hematol. 1997. PMID: 9439979

10

GM-CSF can improve the cytogenetic response obtained with interferon-alpha therapy in patients with chronic myelogenous leukemia.

Cortes J, Kantarjian H, O'Brien S, Kurzrock R, Keating M, Talpaz M. Cortes J, et al. Among authors: talpaz m. Leukemia. 1998 Jun;12(6):860-4. doi: 10.1038/sj.leu.2401033. Leukemia. 1998. PMID: 9639411

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

604 results

Search Page

Filters